John S Markowitz

John S Markowitz, Pharm.D., BCPP

Professor

Department: Pharmacotherapy & Translational Research
Business Phone: (352) 273-6262
Business Email: jmarkowitz@cop.ufl.edu

About John S Markowitz

Dr. Markowitz received his BS in Biology from Memphis State University, and his Doctorate in Pharmacy (Pharm.D.) from the University of Tennessee Center for the Health Sciences (UTCHS). He completed an ASHP-accredited specialty residency in Psychiatric Pharmacy Practice, also at UTCHS. Following his education and training, Dr. Markowitz served for a decade as a Clinical Specialist in Psychiatry, and eventually Clinical Coordinator within the Institute of Psychiatry at the Medical University of South Carolina (MUSC) in Charleston, South Carolina. He eventually transitioned from clinician to a primary faculty research position in the MUSC College of Pharmacy’s Department of Pharmaceutical & Biomedical Sciences with a dual appointment in the Department of Psychiatry and Behavioral Sciences where he had remained prior to joining the UF College of Pharmacy in 2009. Dr. Markowitz has been credentialed by the Board of Pharmaceutical Specialties in Psychiatric Pharmacy (BCPP) since 1997 and is a founding member of the College of Psychiatric and Neurologic Pharmacists (CPNP).

Accomplishments

Outstanding Teaching Team- Year 3 Award, Patient Care VII, Team Leader
2019 · UF College of Pharmacy
Outstanding Teaching Team- Year 3 Award, Patient Care VII, Team Leader
2018 · UF College of Pharmacy
MUSC College of Pharmacy Class of 2008 Professor of the Year
2005-2006 · Medical University of South Carolina (MUSC) College of Pharmacy

Board Certifications

  • Board Certified Psychiatric Pharmacist (BCPP) # 496267
    Board of Pharmaceutical Specialties (BPS)
  • Registered Pharmacist
    Board of Pharmacy-State of Florida

Research Profile

Dr. Markowitz’s research program has encompassed both in vitro and in vivo investigations including normal volunteer pharmacokinetic studies directed at the assessment of drug-drug interactions in psychiatric pharmacy, botanical-drug interactions, as well as their associated clinical effects. More recently, the research program has focused on variability in drug metabolism, disposition, and therapeutic response as a consequence of genetic variability influencing both drug transporters and hepatic enzymes. The serine esterase carboxylesterase 1 (CES1) is of particular interest. Dr. Markowitz has received research support from both the pharmaceutical industry and the National Institutes of Health (NIH) serving as the principal investigator of research grants funded by an array of institutes including NCCAM, NIDA, NIAID, and most recently NICHD. He has authored or co-authored 165 peer-reviewed papers topics in journals such as Clinical Pharmacology & Therapeutics, JAMA, Journal of Clinical Psychopharmacology, J Neurochemistry, Drug Metabolism and Disposition, JPET, and Neuropsychopharmacology.

MARKOWITZ LABORATORY (MSB0445, P Wing, RM P2-32)

The research focus of the Markowitz lab encompasses two primary areas that are somewhat intertwined which relate to individual variability in drug response. These two areas are i) Drug Metabolism and Disposition and ii) Pharmacogenomics. The primary therapeutic area receiving focus from both research themes are neuropsychiatric medications.

Drug Metabolism and Disposition The importance of absorption, distribution, metabolism, and excretion – toxicity (ADMET) of therapeutic agents extends far beyond the initial research and development in Phases I, II, and III within the pharmaceutical industry and well into the post-marketing period. It is this period in which drug exposures go from perhaps less than 5000 individuals to millions of exposures annually. Our program focuses on a variety of environmental factors which govern drug response, tolerability, adverse effects and toxicity. These factors include drug-drug interactions, alcohol-drug interactions, botanical-drug interactions, smoking, and assessment of novel pharmaceutical formulations. Our laboratory relies on a number of investigative approaches including cell culture and novel cell line development for in vitro studies, in vivo animal models, ex vivo approaches, and healthy volunteer pharmacokinetic studies. Further, we also have experience in developing novel LC-MS/MS assays for the detection and quantitation of parent drug and metabolites as well as phytoconstituents of botanical extracts.

Pharmacogenomics of Drug Metabolizing Enzymes and Drug Transporters Genetic mutations can significantly influence the activity and expression of drug metabolizing enzymes (DMEs) as well as the activity of drug transporters. These influences can significantly alter drug absorption and metabolism and lead to adverse events and toxicities, or therapeutic failure. Moreover, prodrug formulations dependent on DMEs for activation may become ineffective in certain circumstances. Our research group discovered and characterized the carboxylesterase 1 (CES1) gene variant, p.Gly143Glu which is arguably the most clinically significant CES1 variant recognized today. The presence of this variant results in markedly reduced activity of the CES1 enzyme, the major hepatic hydrolase responsible for hydrolyzing (inactivating or activating) a wide variety of therapeutic agents. A currently funded research project (1 R01 HD093612-01A1, NICHD) permits us to study the influence of genetic variation in CES1 on the metabolism and response to the psychostimulant, and CES1 substrate, methylphenidate in children with Attention-deficit/hyperactivity disorder (ADHD) A further research theme has been the assessment of the interaction of CNS compounds with the efflux transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) as well as the Organic Cation Transporters (OCT) 1-3 utilizing both cell lines as well as knock-out animal models. As discussed, my lab will perform the analysis of drug concentrations collected from proposed animal experiments, and perform pharmacokinetic analyses.

Publications

2020
Medical Foods-A Closer Look at the Menu: A Brief Review and Commentary.
Clinical therapeutics. 42(7):1416-1423 [DOI] 10.1016/j.clinthera.2020.05.011. [PMID] 32593475.
2020
Natural Products as Modulators of CES1 Activity.
Drug metabolism and disposition: the biological fate of chemicals. 48(10):993-1007 [DOI] 10.1124/dmd.120.000065. [PMID] 32591414.
2020
The influence of carboxylesterase 1 polymorphism and cannabidiol on the hepatic metabolism of heroin.
Chemico-biological interactions. 316 [DOI] 10.1016/j.cbi.2019.108914. [PMID] 31837295.
2019
In Vitro Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites.
Drug metabolism and disposition: the biological fate of chemicals. 47(5):465-472 [DOI] 10.1124/dmd.118.086074. [PMID] 30833288.
2019
New Formulations of Stimulants: An Update for Clinicians.
Journal of child and adolescent psychopharmacology. 29(5):324-339 [DOI] 10.1089/cap.2019.0043. [PMID] 31038360.
2019
The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.
Journal of clinical psychopharmacology. 39(5):462-471 [DOI] 10.1097/JCP.0000000000001089. [PMID] 31433338.
2018
“…Not Intended to Diagnose, Treat, Cure or Prevent Any Disease.” 25 Years of Botanical Dietary Supplement Research and the Lessons Learned.
Clinical pharmacology and therapeutics. 104(3):470-483 [DOI] 10.1002/cpt.1131. [PMID] 29882958.
2018
Relative Bioavailability of Silybin A and Silybin B From 2 Multiconstituent Dietary Supplement Formulations Containing Milk Thistle Extract: A Single-dose Study.
Clinical therapeutics. 40(1):103-113.e1 [DOI] 10.1016/j.clinthera.2017.11.013. [PMID] 29273470.
2017
An Appraisal of Drug-Drug Interactions with Green Tea (Camellia sinensis).
Planta medica. 83(6):496-508 [DOI] 10.1055/s-0043-100934. [PMID] 28118673.
2017
Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers.
Journal of clinical psychopharmacology. 37(4):419-428 [DOI] 10.1097/JCP.0000000000000721. [PMID] 28590363.
2017
Joining the Effort: The Challenges in Establishing Guidelines for Sex- and Gender-specific Research Design in Clinical Therapeutic Studies.
Clinical therapeutics. 39(10):1912-1916 [DOI] 10.1016/j.clinthera.2017.09.005. [PMID] 28942335.
2017
The Clinical Pharmacokinetics of Amphetamines Utilized in the Treatment of Attention-Deficit/Hyperactivity Disorder.
Journal of child and adolescent psychopharmacology. 27(8):678-689 [DOI] 10.1089/cap.2017.0071. [PMID] 28910145.
2017
The effect of milk thistle (Silybum marianum) and its main flavonolignans on CYP2C8 enzyme activity in human liver microsomes.
Chemico-biological interactions. 271:24-29 [DOI] 10.1016/j.cbi.2017.04.025. [PMID] 28457856.
2016
Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.
Journal of child and adolescent psychopharmacology. 26(4):314-26 [DOI] 10.1089/cap.2015.0137. [PMID] 26859445.
2016
CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril.
European journal of clinical pharmacology. 72(6):681-7 [DOI] 10.1007/s00228-016-2029-x. [PMID] 26915813.
2015
An ex vivo approach to botanical-drug interactions: a proof of concept study.
Journal of ethnopharmacology. 163:149-56 [DOI] 10.1016/j.jep.2015.01.021. [PMID] 25623616.
2015
Carboxylesterase 1-mediated drug-drug interactions between clopidogrel and simvastatin.
Biological & pharmaceutical bulletin. 38(2):292-7 [DOI] 10.1248/bpb.b14-00679. [PMID] 25747989.
2015
CNS drugs: the needs are great, the advances, incremental.
Clinical therapeutics. 37(2):272-4 [DOI] 10.1016/j.clinthera.2015.01.004. [PMID] 25727683.
2014
A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorder.
Expert opinion on drug metabolism & toxicology. 10(9):1289-99 [DOI] 10.1517/17425255.2014.939955. [PMID] 25019201.
2014
ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.
Pharmaceutical research. 31(9):2237-55 [DOI] 10.1007/s11095-014-1389-0. [PMID] 24842659.
2014
Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study.
Clinical pharmacology and therapeutics. 96(6):713-22 [DOI] 10.1038/clpt.2014.183. [PMID] 25222620.
2014
Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors.
Journal of pharmaceutical sciences. 103(12):3810-3833 [DOI] 10.1002/jps.24113. [PMID] 25308414.
2014
The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity.
Drug metabolism and disposition: the biological fate of chemicals. 42(10):1611-6 [DOI] 10.1124/dmd.114.057232. [PMID] 25028567.
2014
The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping.
Pharmacogenetics and genomics. 24(8):381-6 [DOI] 10.1097/FPC.0000000000000068. [PMID] 24945780.
2013
An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study.
Drug metabolism and disposition: the biological fate of chemicals. 41(9):1679-85 [DOI] 10.1124/dmd.113.052423. [PMID] 23835761.
2013
Carboxylesterase 1 (CES1) genetic polymorphisms and oseltamivir activation.
European journal of clinical pharmacology. 69(3):733-4 [DOI] 10.1007/s00228-012-1350-2. [PMID] 22847618.
2013
Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation.
The Journal of pharmacology and experimental therapeutics. 344(3):665-72 [DOI] 10.1124/jpet.112.201640. [PMID] 23275066.
2013
Isopropylphenidate: an ester homolog of methylphenidate with sustained and selective dopaminergic activity and reduced drug interaction liability.
Journal of child and adolescent psychopharmacology. 23(10):648-54 [DOI] 10.1089/cap.2013.0074. [PMID] 24261661.
2013
Milk Thistle Herb-Drug Interaction Study: No Effect On Cyp3A, Cyp2C9, and Cyp2D6 Activities in Healthy Participants
Clinical Pharmacology & Therapeutics. 93
2013
Transforming events: hepatic metabolism and individual variability.
Clinical therapeutics. 35(3):202-4 [DOI] 10.1016/j.clinthera.2013.02.016. [PMID] 23497758.
2012
A discriminative analytical method for detection of CES1A1 and CES1A2/CES1A3 genetic variants.
Pharmacogenetics and genomics. 22(3):215-8 [DOI] 10.1097/FPC.0b013e32834f03eb. [PMID] 22237548.
2012
A liquid chromatography/tandem mass spectrometry assay for the analysis of atomoxetine in human plasma and in vitro cellular samples.
Biomedical chromatography : BMC. 26(11):1364-70 [DOI] 10.1002/bmc.2706. [PMID] 22275222.
2012
A sensitive LC-MS/MS assay for the simultaneous analysis of the major active components of silymarin in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 902:1-9 [DOI] 10.1016/j.jchromb.2012.06.003. [PMID] 22766231.
2012
Evaluation of organic cation transporter 3 (SLC22A3) inhibition as a potential mechanism of antidepressant action.
Pharmacological research. 65(4):491-6 [DOI] 10.1016/j.phrs.2012.01.008. [PMID] 22342816.
2012
Limitations of in vitro assessments of the drug interaction potential of botanical supplements.
Planta medica. 78(13):1421-7 [DOI] 10.1055/s-0032-1315025. [PMID] 22814819.
2012
Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.
Pharmaceutical research. 29(4):972-82 [DOI] 10.1007/s11095-011-0637-9. [PMID] 22161308.
2012
Silymarin Reduces Ova-Induced Allergic Airway Inflammation
. 129
2011
An in vitro evaluation of guanfacine as a substrate for P-glycoprotein.
Neuropsychiatric disease and treatment. 7:501-5 [DOI] 10.2147/NDT.S24153. [PMID] 21931492.
2011
Enantiospecific determination of DL-methylphenidate and DL-ethylphenidate in plasma by liquid chromatography-tandem mass spectrometry: application to human ethanol interactions.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 879(11-12):783-8 [DOI] 10.1016/j.jchromb.2011.02.033. [PMID] 21402502.
2011
Pharmacokinetic Profile of Clonidine Hydrochloride Extended-Release Tablets in Children and Adolescents With Attention-Deficit Hyperactivity Disorder
Journal of Child and Adolescent Psychopharmacology. 21
2010
Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions.
Toxicology. 270(2-3):59-65 [DOI] 10.1016/j.tox.2010.01.009. [PMID] 20097249.
2010
Interaction of organic cation transporter 3 (SLC22A3) and amphetamine.
Journal of neurochemistry. 114(1):142-9 [DOI] 10.1111/j.1471-4159.2010.06738.x. [PMID] 20402963.
2009
Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants.
Drug metabolism and disposition: the biological fate of chemicals. 37(2):264-7 [DOI] 10.1124/dmd.108.024943. [PMID] 19022936.
2009
Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver.
Drug metabolism and disposition: the biological fate of chemicals. 37(9):1819-25 [DOI] 10.1124/dmd.109.028209. [PMID] 19487248.
2009
All-sky LIGO search for periodic gravitational waves in the early fifth-science-run data.
Physical review letters. 102(11) [PMID] 19392186.
View on: PubMed
2009
An upper limit on the stochastic gravitational-wave background of cosmological origin.
Nature. 460(7258):990-4 [DOI] 10.1038/nature08278. [PMID] 19693079.
2009
Aripiprazole brain concentration is altered in P-glycoprotein deficient mice.
Schizophrenia research. 110(1-3):90-4 [DOI] 10.1016/j.schres.2009.01.011. [PMID] 19239981.
2009
Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril.
Biochemical pharmacology. 77(7):1266-72 [DOI] 10.1016/j.bcp.2008.12.017. [PMID] 19185566.
2009
The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT(1A) receptor.
Die Pharmazie. 64(2):123-5 [PMID] 19322953.
View on: PubMed
2008
Antipsychotic drugs inhibit the function of breast cancer resistance protein.
Basic & clinical pharmacology & toxicology. 103(4):336-41 [DOI] 10.1111/j.1742-7843.2008.00298.x. [PMID] 18834354.
2008
Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?
Journal of clinical psychopharmacology. 28(3 Suppl 2):S54-61 [DOI] 10.1097/JCP.0b013e3181733560. [PMID] 18480678.
2008
Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 862(1-2):140-9 [PMID] 18155648.
View on: PubMed
2008
Given the multifaceted nature of ADHD, namely its physiologic, cognitive, psychological, and behavioral manifestations, multimodal approaches to treatment are advocated. Introduction.
Journal of clinical psychopharmacology. 28(3 Suppl 2):S37-8 [DOI] 10.1097/JCP.0b013e3181733143. [PMID] 18480675.
2008
Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.
European journal of pharmacology. 578(2-3):148-58 [PMID] 17963743.
View on: PubMed
2008
Predicting interactions between conventional medications and botanical products on the basis of in vitro investigations.
Molecular nutrition & food research. 52(7):747-54 [DOI] 10.1002/mnfr.200700159. [PMID] 18324706.
2008
Search for gravitational-wave bursts from soft gamma repeaters.
Physical review letters. 101(21) [PMID] 19113401.
View on: PubMed
2008
Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein.
Biological & pharmaceutical bulletin. 31(2):231-4 [PMID] 18239278.
View on: PubMed
2008
Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis.
American journal of human genetics. 82(6):1241-8 [DOI] 10.1016/j.ajhg.2008.04.015. [PMID] 18485328.
2007
A novel HPLC fluorescence method for the quantification of methylphenidate in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 858(1-2):91-5 [PMID] 17804308.
View on: PubMed
2007
Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study.
Schizophrenia research. 93(1-3):131-5 [PMID] 17391930.
View on: PubMed
2007
Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics.
Clinical pharmacology and therapeutics. 81(3):346-53 [PMID] 17339864.
View on: PubMed
2007
Risperidone and paliperidone inhibit p-glycoprotein activity in vitro.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 32(4):757-64 [PMID] 16936711.
View on: PubMed
2007
Sensitive quantification of atomoxetine in human plasma by HPLC with fluorescence detection using 4-(4,5-diphenyl-1H-imidazole-2-yl) benzoyl chloride derivatization.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 846(1-2):351-4 [PMID] 16949894.
View on: PubMed
2007
Sex differences in the response of children with ADHD to once-daily formulations of methylphenidate.
Journal of the American Academy of Child and Adolescent Psychiatry. 46(6):701-710 [DOI] 10.1097/chi.0b013e31804659f1. [PMID] 17513982.
2006
A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study.
Journal of child and adolescent psychopharmacology. 16(6):687-98 [PMID] 17201613.
View on: PubMed
2006
Agave (Agave americana): an evidence-based systematic review by the natural standard research collaboration.
Journal of herbal pharmacotherapy. 6(2):101-22 [PMID] 17182489.
View on: PubMed
2006
Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana.
The Journal of pharmacology and experimental therapeutics. 317(2):850-7 [PMID] 16439618.
View on: PubMed
2006
Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder.
The international journal of neuropsychopharmacology. 9(5):603-5 [PMID] 16202177.
View on: PubMed
2006
Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.
Psychopharmacology. 187(4):415-23 [PMID] 16810505.
View on: PubMed
2006
Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers.
Journal of clinical pharmacology. 46(2):164-71 [PMID] 16432268.
View on: PubMed
2006
Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice.
Psychopharmacology. 183(4):490-9 [PMID] 16283256.
View on: PubMed
2006
The role of the polymorphic efflux transporter P-glycoprotein on the brain accumulation of d-methylphenidate and d-amphetamine.
Drug metabolism and disposition: the biological fate of chemicals. 34(7):1116-21 [PMID] 16621932.
View on: PubMed
2005
Effect of Ginkgo biloba extract on plasma steroid concentrations in healthy volunteers: a pilot study.
Pharmacotherapy. 25(10):1337-40 [PMID] 16185177.
View on: PubMed
2005
Effects of St John’s wort (Hypericum perforatum L.) extract on plasma androgen concentrations in healthy men and women: a pilot study.
Phytotherapy research : PTR. 19(10):901-6 [PMID] 16261523.
View on: PubMed
2005
Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C.
Journal of viral hepatitis. 12(2):176-85 [PMID] 15720533.
View on: PubMed
2005
New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder.
Expert opinion on drug delivery. 2(1):121-43 [PMID] 16296740.
View on: PubMed
2005
Oral administration of a decaffeinated green tea (Camellia sinensis) extract did not alter urinary 8-epi-prostaglandin F(2 alpha), a biomarker for in-vivo lipid peroxidation.
The Journal of pharmacy and pharmacology. 57(10):1365-9 [PMID] 16259767.
View on: PubMed
2005
P-glycoprotein does not actively transport nicotine and cotinine.
Addiction biology. 10(2):127-9 [PMID] 16191663.
View on: PubMed
2005
Short-term administration of (-)-epigallocatechin gallate reduces hepatic steatosis and protects against warm hepatic ischemia/reperfusion injury in steatotic mice.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 11(3):298-308 [PMID] 15719408.
View on: PubMed
2004
Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder.
Pharmacotherapy. 24(8):1020-36 [PMID] 15338851.
View on: PubMed
2004
Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice.
Psychopharmacology. 173(1-2):132-8 [PMID] 14712343.
View on: PubMed
2004
Common herbal supplements did not produce false-positive results on urine drug screens analyzed by enzyme immunoassay.
Journal of analytical toxicology. 28(4):272-3 [PMID] 15189680.
View on: PubMed
2004
Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers.
Journal of clinical psychopharmacology. 24(1):4-10 [PMID] 14709940.
View on: PubMed
2004
Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers.
Drug metabolism and disposition: the biological fate of chemicals. 32(9):906-8 [PMID] 15319329.
View on: PubMed
2004
Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers.
Drug metabolism and disposition: the biological fate of chemicals. 32(12):1333-6 [PMID] 15328251.
View on: PubMed
2004
Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 29(3):551-7 [PMID] 14702023.
View on: PubMed
2004
The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein.
The international journal of neuropsychopharmacology. 7(4):415-9 [PMID] 15683552.
View on: PubMed
2003
Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations.
Pharmacotherapy. 23(10):1281-99 [PMID] 14594346.
View on: PubMed
2003
Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study.
Neurocase. 9(3):274-82 [PMID] 12925933.
View on: PubMed
2003
Chiral analysis of d- and l-modafinil in human serum: application to human pharmacokinetic studies.
Therapeutic drug monitoring. 25(2):197-202 [PMID] 12657914.
View on: PubMed
2003
Dietary levels of quinine in tonic water do not inhibit CYP2D6 in vivo.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 41(8):1199-201 [PMID] 12842189.
View on: PubMed
2003
Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme.
JAMA. 290(11):1500-4 [PMID] 13129991.
View on: PubMed
2003
Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers.
Clinical pharmacology and therapeutics. 74(2):170-7 [PMID] 12891227.
View on: PubMed
2003
Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers.
Clinical pharmacology and therapeutics. 74(6):536-42 [PMID] 14663456.
View on: PubMed
2003
Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers.
Journal of clinical psychopharmacology. 23(6):576-81 [PMID] 14624188.
View on: PubMed
2003
Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
Clinical pharmacokinetics. 42(4):393-401 [PMID] 12648029.
View on: PubMed
2003
Siberian ginseng (Eleutheroccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers.
Drug metabolism and disposition: the biological fate of chemicals. 31(5):519-22 [PMID] 12695337.
View on: PubMed
2002
Clinical pharmacokinetics of sertraline.
Clinical pharmacokinetics. 41(15):1247-66 [PMID] 12452737.
View on: PubMed
2002
Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers.
Journal of clinical psychopharmacology. 22(2):169-73 [PMID] 11910262.
View on: PubMed
2002
Hypotension and bradycardia in a healthy volunteer following a single 5 mg dose of olanzapine.
Journal of clinical pharmacology. 42(1):104-6 [PMID] 11808820.
View on: PubMed
2002
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.
Life sciences. 71(2):163-9 [PMID] 12031686.
View on: PubMed
2002
Psychoactive drug interactions with pharmacotherapy for diabetes.
Psychopharmacology bulletin. 36(2):40-52 [PMID] 12397839.
View on: PubMed
2002
Selective serotonin reuptake inhibitor-induced rash: case report and review of the literature.
Pharmacotherapy. 22(4):516-8 [PMID] 11939687.
View on: PubMed
2002
The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers.
Clinical pharmacology and therapeutics. 71(1):30-8 [PMID] 11823755.
View on: PubMed
2001
A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates.
Neurocase. 7(2):105-10 [PMID] 11320158.
View on: PubMed
2001
A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine.
Journal of chromatography. B, Biomedical sciences and applications. 759(2):319-23 [PMID] 11499485.
View on: PubMed
2001
Charleston Antidepressant Drug Interactions Surveillance Program (CADISP).
Psychopharmacology bulletin. 35(2):50-61 [PMID] 12397886.
View on: PubMed
2001
Drug glucuronidation in clinical psychopharmacology.
Journal of clinical psychopharmacology. 21(5):500-15 [PMID] 11593076.
View on: PubMed
2001
Lack of citalopram effect on the pharmacokinetics of cyclosporine.
Psychosomatics. 42(4):370-2 [PMID] 11496034.
View on: PubMed
2001
Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 7(8):745-9 [PMID] 11510023.
View on: PubMed
2001
Methylphenidate ER tablet lodging in esophagus.
Journal of the American Academy of Child and Adolescent Psychiatry. 40(11):1244-5 [PMID] 11699796.
View on: PubMed
2001
New onset diabetes and atypical antipsychotics.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 11(1):25-32 [PMID] 11226809.
View on: PubMed
2001
Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.
Clinical pharmacokinetics. 40(10):753-72 [PMID] 11707061.
View on: PubMed
2001
The emerging recognition of herb-drug interactions with a focus on St. John’s wort (Hypericum perforatum).
Psychopharmacology bulletin. 35(1):53-64 [PMID] 12397870.
View on: PubMed
2000
An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram.
International clinical psychopharmacology. 15(6):329-33 [PMID] 11110008.
View on: PubMed
2000
Avoiding psychotropic drug interactions in the cardiovascular patient.
Bulletin of the Menninger Clinic. 64(1):49-59 [PMID] 10695159.
View on: PubMed
2000
Effect of St. John’s wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers.
Life sciences. 66(9):PL133-9 [PMID] 10698361.
View on: PubMed
2000
Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol.
Drug metabolism and disposition: the biological fate of chemicals. 28(6):620-4 [PMID] 10820132.
View on: PubMed
2000
Oral nutritional supplementation for the alcoholic patient: a brief overview.
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. 12(3):153-8 [PMID] 10984005.
View on: PubMed
2000
Rifampin-induced selective serotonin reuptake inhibitor withdrawal syndrome in a patient treated with sertraline.
Journal of clinical psychopharmacology. 20(1):109-10 [PMID] 10653222.
View on: PubMed
2000
Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers.
Journal of clinical psychopharmacology. 20(3):347-9 [PMID] 10831022.
View on: PubMed
2000
Successful liver transplantation in a patient with Budd-Chiari syndrome caused by homozygous factor V Leiden.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 6(5):654-6 [PMID] 10980068.
View on: PubMed
1999
A simple model to estimate survival after retransplantation of the liver.
Transplantation. 67(3):422-30 [PMID] 10030290.
View on: PubMed
1999
Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy.
The Annals of pharmacotherapy. 33(1):73-85 [PMID] 9972387.
View on: PubMed
1999
Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs.
The Annals of pharmacotherapy. 33(2):210-7 [PMID] 10084417.
View on: PubMed
1999
Clozapine-associated elevation in serum triglycerides.
The American journal of psychiatry. 156(8):1270-2 [PMID] 10450273.
View on: PubMed
1999
Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion.
Journal of clinical psychopharmacology. 19(4):362-6 [PMID] 10440465.
View on: PubMed
1999
Drug interactions with psychostimulants.
International clinical psychopharmacology. 14(1):1-18 [PMID] 10221637.
View on: PubMed
1999
Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions.
Pharmacotherapy. 19(5):565-72 [PMID] 10331819.
View on: PubMed
1999
Possible dihydroepiandrosterone-induced mania.
Biological psychiatry. 45(2):241-2 [PMID] 9951574.
View on: PubMed
1999
Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration.
Journal of clinical psychopharmacology. 19(3):289-91 [PMID] 10350045.
View on: PubMed
1998
Atypical antipsychotics.
Journal of the American Academy of Child and Adolescent Psychiatry. 37(12):1243-4 [PMID] 9847493.
View on: PubMed
1998
Lack of antidepressant-cyclosporine pharmacokinetic interactions.
Journal of clinical psychopharmacology. 18(1):91-3 [PMID] 9472853.
View on: PubMed
1998
Priapism following trazodone overdose with cocaine use.
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. 10(2):81-3 [PMID] 9669540.
View on: PubMed
1998
Selective serotonin reuptake inhibitor discontinuation with ECT and withdrawal symptoms.
The journal of ECT. 14(1) [PMID] 9661096.
View on: PubMed
1998
Sumatriptan for post-ECT headache.
The journal of ECT. 14(4):272-4 [PMID] 9871850.
View on: PubMed
1998
Venlafaxine-tramadol similarities.
Medical hypotheses. 51(2):167-8 [PMID] 9881825.
View on: PubMed
1997
Antipsychotic blood concentrations: nonstandardization of reference ranges.
Journal of clinical psychopharmacology. 17(2):121-4 [PMID] 10950479.
View on: PubMed
1997
Awareness of potential drug interactions may aid avoidance.
Therapeutic drug monitoring. 19(3):366-7 [PMID] 9200782.
View on: PubMed
1997
Clonidine dependence.
Journal of clinical psychopharmacology. 17(2):137-8 [PMID] 10950490.
View on: PubMed
1997
Clozapine-fluroxamine interaction.
Clinical neuropharmacology. 20(3):281-2 [PMID] 9197954.
View on: PubMed
1997
Drug interaction potential of fluoxetine, sertraline, and paroxetine in four state psychiatric hospital populations.
Therapeutic drug monitoring. 19(2):244-5 [PMID] 9108660.
View on: PubMed
1997
Fluoroquinolone inhibition of clozapine metabolism.
The American journal of psychiatry. 154(6) [PMID] 9167522.
View on: PubMed
1997
Fluvoxamine-induced theophylline toxicity.
The American journal of psychiatry. 154(9):1317-8 [PMID] 9286199.
View on: PubMed
1997
Gabapentin abuse in a cocaine user: implications for treatment?
Journal of clinical psychopharmacology. 17(5):423-4 [PMID] 9315994.
View on: PubMed
1997
Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): evidence for heterogeneity.
Hepatology (Baltimore, Md.). 26(1):155-64 [PMID] 9214465.
View on: PubMed
1997
Marked liver enzyme elevations with clozapine.
Journal of clinical psychopharmacology. 17(1):70-1 [PMID] 9004073.
View on: PubMed
1997
Potential for overestimation of clozapine concentrations.
Journal of analytical toxicology. 21(1):73-5 [PMID] 9013297.
View on: PubMed
1997
The impact of microsurgical hepatic arterial reconstruction on the outcome of liver transplantation for congenital biliary atresia.
American journal of surgery. 173(5):431-5 [PMID] 9168083.
View on: PubMed
1996
“Smart drugs”?
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. 8(1):41-2 [PMID] 8743649.
View on: PubMed
1996
Fluvoxamine-clozapine dose-dependent interaction.
Canadian journal of psychiatry. Revue canadienne de psychiatrie. 41(10):670-1 [PMID] 8978949.
View on: PubMed
1996
Polypharmacy side effects.
Journal of the American Academy of Child and Adolescent Psychiatry. 35(7) [PMID] 8768342.
View on: PubMed
1996
Stuttering with sertraline.
The Journal of clinical psychiatry. 57(2):90-1 [PMID] 8591976.
View on: PubMed
1996
Use of clozapine with nonresponsive patients.
Psychiatric services (Washington, D.C.). 47(12) [PMID] 9117483.
View on: PubMed
1996
Zolpidem-induced psychosis.
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. 8(2):89-91 [PMID] 8807033.
View on: PubMed
1995
Delirium associated with clozapine and benzodiazepine combinations.
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. 7(3):139-41 [PMID] 8646274.
View on: PubMed
1995
Interactions between antipsychotic and antihypertensive drugs.
The Annals of pharmacotherapy. 29(6):603-9 [PMID] 7663034.
View on: PubMed
1995
SIADH associated with fluoxetine and sertraline therapy.
The American journal of psychiatry. 152(5):809-10 [PMID] 7726326.
View on: PubMed
1995
Significance of plasma thiothixene concentrations.
The Annals of pharmacotherapy. 29(7-8):789-90 [PMID] 8520104.
View on: PubMed
1995
Thermal degradation of clozapine-N-oxide to clozapine during gas chromatographic analysis.
Journal of chromatography. B, Biomedical applications. 668(1):171-4 [PMID] 7550974.
View on: PubMed
1993
Determinants for hospitalization from an emergency mental health service.
Journal of the American Academy of Child and Adolescent Psychiatry. 32(1):114-22 [PMID] 8428863.
View on: PubMed
1992
General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research.
Journal of clinical psychopharmacology. 12(1):3-10 [PMID] 1552037.
View on: PubMed
1989
Diagnostic criteria for dysthymic disorder.
Psychopharmacology bulletin. 25(3):325-9 [PMID] 2697006.
View on: PubMed
1989
Gas chromatographic-mass spectrometric analysis of plasma oxybutynin using a deuterated internal standard.
Journal of chromatography. 487(1):91-8 [PMID] 2715278.
View on: PubMed
1989
Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression.
Archives of general psychiatry. 46(9):787-93 [PMID] 2673130.
View on: PubMed
1988
Antidepressant specificity in atypical depression.
Archives of general psychiatry. 45(2):129-37 [PMID] 3276282.
View on: PubMed
1987
A comparative study of the electrocardiographic effects of phenelzine, tricyclic antidepressants, mianserin, and placebo.
Journal of clinical psychopharmacology. 7(5):335-9 [PMID] 3680604.
View on: PubMed
1987
Validity assessment of SAFTEE: a preliminary report.
Psychopharmacology bulletin. 23(1):102-5 [PMID] 3299444.
View on: PubMed
1986
Follow-up of patients who improved during placebo washout.
Journal of clinical psychopharmacology. 6(5):274-8 [PMID] 3771808.
View on: PubMed
1986
How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine.
Psychiatry research. 19(1):75-86 [PMID] 3538107.
View on: PubMed
1986
Side effect assessment with SAFTEE: pilot study of the instrument.
Psychopharmacology bulletin. 22(2):389-96 [PMID] 3774932.
View on: PubMed
1985
Attrition and its consequences in a clinical trial of placebo, imipramine, and phenelzine.
Psychopharmacology bulletin. 21(1):107-9 [PMID] 3885288.
View on: PubMed
1985
Effect of panic attacks on the treatment of atypical depressives.
Psychopharmacology bulletin. 21(3):558-61 [PMID] 4034874.
View on: PubMed
1985
Incidence of aplastic anemia in metropolitan Baltimore: a population-based study.
Blood. 66(1):115-9 [PMID] 4005425.
View on: PubMed
1984
Phenelzine v imipramine in atypical depression. A preliminary report.
Archives of general psychiatry. 41(7):669-77 [PMID] 6375621.
View on: PubMed
1984
Psychopharmacologic validation of atypical depression.
The Journal of clinical psychiatry. 45(7 Pt 2):22-5 [PMID] 6376483.
View on: PubMed

Grants

Sep 2020 ACTIVE
Medical Marijuana Use and Driving Performance: A Test of Psychomotor Function in Adults 50 and Older
Role: Co-Investigator
Funding: FL STATE UNIV via NATL INST OF HLTH NIDA
Aug 2018 ACTIVE
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
Role: Principal Investigator
Funding: NATL INST OF HLTH NICHD
Apr 2015 – Mar 2018
Relative Bioavailability of Two different Milk Thistle Formulations: A Single Dose Randomized Crossover Pharmacokinetic Study
Role: Principal Investigator
Funding: ISAGENIX INTERNATIONAL LLC

Patents

Published October 2013
Compositions and Methods for Genotyping CES1 Genetic Variants and Use Thereof
#US2014-0162896 A1

Education

Psychiatric Pharmacy Residency
1991 · University of Tennessee College of Pharmacy, Memphis, Tennessee
Pharm.D.
1990 · University of Tennessee
B.S.
1984 · Memphis State University

Teaching Profile

Courses Taught
2020-2021
PHA6910 Supervised Research
2013-2017,2019-2021
PHA7979 Advanced Research
2013-2017,2019-2021
PHA7980 Research for Doctoral Dissertation
2018,2020
PHA6427 Pharmacogenetics of Drug Metabolism
2017-2019
PHA5737 Drugs in Society
2018-2019,2021
PHA5789C Patient Care 7
2018
PHA5439 Prin Med Chem-Pcol I
2018
PHA5166L Prof Skills Lab Vi
2014-2017,2021
PHA6938 Research Seminar
2016
PHA5598 Care/Patient Psychia
2012-2016
PHA5113 Personalized Medicine
2016
PHA6971 Research for Master’s Thesis
2011-2015
PHA5782 Pharmacotherapy 2
2014
PHA5907 Research in Phar Prac
2012-2013
PHA5783 Pharmacotherapy 3
2011
PHA5113C Thera Mon/Pharmacogen

Contact Details

Phones:
Business:
(352) 273-6262
Emails: